1. A DNA methylation-based definition of biologically distinct breast cancer subtypes.

    Molecular Oncology 9(3):555 (2015) PMID 25468711

    In cancer, epigenetic states are deregulated and thought to be of significance in cancer development and progression. We explored DNA methylation-based signatures in association with breast cancer subtypes to assess their impact on clinical presentation and patient prognosis. DNA methylation was...
  2. CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal/triple-negative breast cancer.

    Epigenetics 6(5):638 (2011) PMID 21593597 PMCID PMC3121973

    Triple-negative breast cancer (TNBC) occurs in approximately 15% of all breast cancer patients, and the incidence of TNBC is greatly increased in BRCA1 mutation carriers. This study aimed to assess the impact of BRCA1 promoter methylation with respect to breast cancer subtypes in sporadic diseas...
  3. Breast cancer risk associated with AURKA 91T -->A polymorphism in relation to BRCA mutations.

    Cancer Letters 250(2):206 (2007) PMID 17113223

    In this study 759 breast cancer patients, including 9 BRCA1 and 98 BRCA2 mutation carriers, and 653 mutation-negative unaffected controls were genotyped for the AURKA 91T -->A polymorphism. Individuals homozygous for the 91A allele were found to be at increased risk of breast cancer compared to ...
  4. Aurora-A amplification associated with BRCA2 mutation in breast tumours.

    Cancer Letters 248(1):96 (2007) PMID 16860930

    Potential interaction of Aurora-A amplification and BRCA2 mutation was examined in breast tumours from BRCA2 999del5 mutation carriers (n=20) and non-carriers (n=41). Aurora-A amplification studied by FISH was significantly more common in breast tumours from BRCA2 mutation carriers (p=0.0005). E...
  5. MYCamplification and TERT expression in breast tumor progression

    Cancer Genetics and Cytogenetics 176(2):93 (2007)

    The complex roles of genomic instability, MYC oncogene amplification, activation of telomerase, and p53 function still remain to be fully described in breast tumors. MYC stimulates the telomerase catalytic subunit, TERT, which interacts with p53. Oncogene MYC amplificat...
  6. Breast cancer risk associated withAURKA91T → A polymorphism in relation toBRCAmutations

    Cancer Letters 250(2):206 (2007)

    In this study 759 breast cancer patients, including 9 BRCA1 and 98 BRCA2 mutation carriers, and 653 mutation-negative unaffected controls were genotyped for the AURKA 91T → A polymorphism. Individuals homozygous for the 91A allele were found to be at increas...
  7. Effect of hypoxia and TP53 mutation status and cytogenetics of normal and malignant mammary epithelium.

    Cancer Genetics and Cytogenetics 165(2):144 (2006) PMID 16527608

    It has been proposed that hypoxia favors the growth of tumor cells over normal cells, particularly tumor cells carrying TP53 mutations. Cytogenetic studies of breast cancer have shown that highly complex karyotypes seen in direct harvest preparations are rarely detected after short-term culture....
  8. Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer.

    Breast Cancer Research (Online Edition) 8(4):R38 (2006) PMID 16846527 PMCID PMC1779478

    BRCA1 or BRCA2 germline mutations increase the risk of developing breast cancer. Tumour cells from germline mutation carriers have frequently lost the wild-type allele. This is predicted to result in genomic instability where cell survival depends upon dysfunctional checkpoint mechanisms. Tumori...
  9. Effect of hypoxia andTP53mutation status and cytogenetics of normal and malignant mammary epithelium

    Cancer Genetics and Cytogenetics 165(2):144 (2006)

    It has been proposed that hypoxia favors the growth of tumor cells over normal cells, particularly tumor cells carrying TP53 mutations. Cytogenetic studies of breast cancer have shown that highly complex karyotypes seen in direct harvest preparations are rarely detected after short-t...